Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

188
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
188
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

361
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
361
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

180
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
180
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

249
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
249
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.7K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.7K
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

212
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
212

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing quantitative clinical pharmacology competencies in Francophone Africa through an on-line learning framework.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

Best Practices in Physiologically Based Pharmacokinetic (PBPK) Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Application of Virtual Twin PBPK Models in Individuals with Obesity via CYP3A4 Phenotyping Using Endogenous Biomarker Data.

Clinical pharmacology and therapeutics·2026
Same author

Proteomics-Informed Physiologically Based Pharmacokinetic Modeling for Aldehyde Oxidase Substrates in Colorectal Cancer Liver Metastasis.

Molecular pharmaceutics·2026
Same author

Overlooked aspects of scaling enzyme activity through abundance across tissues and individuals: Insights from k<sub>cat</sub> measurements in matched liver and intestinal samples.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Application of modelling of cell monolayer permeation data to generate input parameters compatible with in vitro-in vivo translation of blood-brain-barrier disposition of drugs.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026

Related Experiment Video

Updated: Dec 6, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.9K

Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method.

Jennifer Lang1, Ludwig Vincent2, Marylore Chenel3

  • 1Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PT, UK.

The AAPS Journal
|October 9, 2020
PubMed
Summary
This summary is machine-generated.

This study developed a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for ivabradine and its metabolite. The model accurately predicts drug concentrations and heart rate reduction, including drug-drug interactions with CYP3A4 inhibitors.

Keywords:
Bayesian analysisdrug-drug interactionsivabradineparent-metabolitephysiologically based pharmacokinetic modelling

More Related Videos

High-Throughput Metabolic Profiling for Model Refinements of Microalgae
11:07

High-Throughput Metabolic Profiling for Model Refinements of Microalgae

Published on: December 4, 2021

4.1K
Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
07:41

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Published on: June 5, 2017

10.2K

Related Experiment Videos

Last Updated: Dec 6, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.9K
High-Throughput Metabolic Profiling for Model Refinements of Microalgae
11:07

High-Throughput Metabolic Profiling for Model Refinements of Microalgae

Published on: December 4, 2021

4.1K
Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
07:41

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Published on: June 5, 2017

10.2K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Computational Modeling
  • Drug Metabolism and Interactions

Background:

  • Ivabradine and its metabolite inhibit the If current, reducing heart rate.
  • Both compounds undergo metabolism via Cytochrome P450 3A4 (CYP3A4).
  • Understanding their pharmacokinetic (PK) and pharmacodynamic (PD) profiles is crucial, especially with CYP3A4 inhibitors.

Purpose of the Study:

  • To develop a joint parent-metabolite physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model.
  • To predict the PK and PD of ivabradine and its metabolite after intravenous or oral administration.
  • To assess drug-drug interactions (DDIs) with CYP3A4 inhibitors.

Main Methods:

  • Developed a parent-metabolite disposition model using Bayesian analysis of plasma concentration-time data.
  • Integrated a mechanistic intestinal model to simulate oral absorption and DDIs with ketoconazole and grapefruit juice.
  • Linked the PBPK model to a PD model using simulated unbound concentrations in the heart to predict heart rate reduction.

Main Results:

  • The disposition model accurately described parent-metabolite PK after intravenous administration.
  • The PBPK model successfully predicted plasma concentration profiles and DDI risks (92% and 85% for AUC and Cmax ratios).
  • The integrated PBPK/PD model accurately predicted heart rate reduction in control and ketoconazole groups.

Conclusions:

  • A robust PBPK/PD modeling framework for parent-metabolite systems was established.
  • The model effectively predicts ivabradine PK/PD and DDI potential.
  • This framework can be applied to other populations and untested scenarios, including DDI risk assessment.